Moxifloxacine Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacine Fresenius Kabi, is a fluoroquinolone presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in hospitalized patients, including pneumonia, intra‑abdominal infections and skin infections.

GNH USA supplies Moxifloxacine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacine Fresenius Kabi is a fluoroquinolone antibacterial used for several serious infections. - Community‑acquired pneumonia: provides rapid bacterial eradication and clinical improvement. - Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic pathogens to resolve infection. - Skin and soft tissue infections: effective against common Gram‑positive and Gram‑negative organisms. - Acute bacterial sinusitis: helps clear infection when oral therapy is insufficient.

Moxifloxacine Fresenius Kabi may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensations. - Rash: mild skin erythema. - Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, especially in weight‑bearing tendons. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but potentially life‑threatening liver injury.

When using Moxifloxacine Fresenius Kabi, clinicians should consider several safety measures. - Renal function: assess and adjust in severe impairment. - Cardiac risk: monitor QT interval in patients with known prolongation or electrolyte disturbances. - Concomitant QT‑prolonging drugs: avoid or use with caution. - Pregnancy: prescribe only if benefits outweigh potential risks. - Tendon health: advise patients to report new tendon pain or swelling. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacine Fresenius Kabi can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other fluoroquinolones: avoid duplication of class effect. - Drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): increase risk of arrhythmia. - Systemic corticosteroids: heightened risk of tendon rupture.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect alteration. - Theophylline: observe for increased serum concentrations. - Antacids containing aluminum or magnesium (if oral formulation were used): may reduce absorption, though less relevant for IV use.